Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)

A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanced Renal Cancer.

Trial Details

NCT ID
NCT07770802
Phase
PHASE1
Sponsor
Hangzhou Huasai Biomedicine Co., Ltd.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cyclophosphamid
  • Fludarabine
  • Interleukin 2 subcutaneous injection
  • HS-IT101 monotherapy
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Aged 18 to 75 years old, regardless of gender;
  • Pathologically confirmed by histology and/or cytology as metastatic or unresectable clear cell renal cell carcinoma (defined as clear cell componen…
  • Before screening, there is at least one biopsiable lesion that has not received radiation therapy or other local treatments (such as ablation thera…
  • After tumor tissue sampling, there is at least one measurable tumor lesion defined by the RECIST 1.1 criteria (Lesions located in areas that have r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →